Six proposals were not heard during the Coordination and Maintenance committee meeting.
The Coordination and Maintenance Committee Meeting was held March 9 – 10, 2021. The meeting began with discussion of the ICD-10-PCS topics. There were six proposals that were not discussed during the meeting which were therapeutic administration of drugs/substances. This article will review the six proposals. Remember that all comments for all procedure topics are due April 9, 2021. The comments should be sent to ICDProcedureCodeRequest@cms.hhs.gov.
The first proposal was for the administration of Amivantamab which is used to treat epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer with Exon20 insertions. The five-year survival rate is 8 percent with this type of cancer. This drug is a fully human bispecific antibody that binds to the extracellular domains of the epidermal growth factor and mesenchymal epithelial transition (MET). It is administered on a 28-day cycle on an outpatient basis. Patients may need to be administered if admitted for other complications of the disease. This drug has been designated as a breakthrough therapy and is currently working through clinical trials.
The second proposal is for the administration of Ciltacabtagene Autoleucel which is a B-cell maturation Antigen Directed CAR T-cell Therapy. This drug treats relapsed/refractory multiple myeloma. It takes approximately 57 days from registration to complete the initial round of therapy. There is a PCS code for CAR T-cell therapy, but not specific to this type of therapy.
The third proposal is ENSPRYNG (satralizumab mwge) which is a humanized IgG2 monoclonal antibody which is used for treating Neuromyelitis Optica Spectrum Disorder (NMOSD). Patients with this disorder relapsed 60% within one year and 90 percent within three years. These patients required wheelchairs (50 percent) and could be functionally blind (62percent). In the study, there was significant reduction in relapse. This medication is given subcutaneously as an inpatient or outpatient. After a loading dose, the medication is administered every four weeks.
The fourth proposal is administration of Trilaciclib which is a myelopreservation therapy. The goal of this therapy is to mitigate chemotherapy induced myelosuppression in extensive non-small cell lung cancer patients. Trilaciclib has been granted FDA breakthrough therapy status. This medication is administered intravenously or via central line. Patients are treated with four cycles of 21-day therapy. The patient is given chemotherapy with Trilaciclib days 1 – 3 followed by 18 days treatment free. One inpatient admission is expected, but the medication can be administered as an inpatient or outpatient.
The fifth proposal is administration of ZEPZELCA (lurbinectedin) which is a transcription inhibitor for patients with metastatic small cell lung carcinoma. This is a second line option whose cancer has progressed while on traditional chemotherapy. This medication has been approved by the Federal Drug Administration (FDA). The schedule for this medication is every 21 days. It can be administered on an inpatient or outpatient basis.
The last proposal is the transfusion of pathogen reduced cryoprecipitated fibrinogen complex (PRCFC) which is used to treat massive bleeding when patient is fibrinogen deficient. This substance is not the same as the usual cryoprecipitate. This substance has been approved by the FDA and was awarded breakthrough device designation. PRCFC is treated by INTERCEPT Blood System which inactivates pathogens to reduce transfusion transmitted infections (TTI). This product has a five-day at room temperature shelf-life.
These six drugs/products have requested New Technology Add-On Payment (NTAP) which provides additional reimbursement to the Medicare-Severity Diagnosis Related Group (MS-DRG). In proposed rule for Inpatient Prospective Payment System (IPPS) FY22, a preliminary recommendation will be published. These procedure codes are being considered for FY22 which begins Oct. 1, 2021.
Programming Note: Listen to Laurie Johnson report this story live today during Talk Ten Tuesdays, 10 a.m. Eastern.
The Coordination and Maintenance (C&M) Committee meeting was held on Sept. 12 and 13. The meeting began with the procedure proposals, which were followed by
The next Coordination and Maintenance (C&M) Committee meeting will be held on Sept. 12 and 13 . This meeting will be virtual, and you must
Please log in to your account to comment on this article.
Uncover essential coding insights with nationally recognized coding authority Kay Piper, RHIA, CDIP, CCS. Through ICD10monitor’s interactive, on‑demand webcast series, Kay walks you through the AHA’s 2026 ICD‑10‑CM/PCS Quarterly Coding Clinics, translating each update into practical, easy‑to‑apply guidance designed to sharpen precision, ensure compliance, and strengthen day‑to‑day decision‑making. Available shortly after each official release.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s fourth quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s third quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s second quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
BLOOM INTO SAVINGS! Get 25% OFF during our spring sale through March 27. Use code SPRING26 at checkout to claim this offer.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
